Vancouver, B.C. August 28, 2020 – Benchmark Botanics, Inc. (CSE: BBT) (“Benchmark” or the “Company”) a cannabis producer, today released its financial and operational results for the second quarter ended June 30, 2020.

2020 Q2 Highlights

• Achieved record revenue for the first six months of the year with $278,515 of revenue,
• Obtain its Nursery Seed License to provide additional revenue opportunities in genetics, and
• Shortly after the end of Q2 obtained it’s third cultivation license for its joint venture facility with Zhejiang Yatai Pharmaceutical Co. Ltd.

Results of Operations
The following table sets forth consolidated statements of operations, which is expressed in Canadian dollars, except share and per share amounts, for the indicated periods.

 

Total revenue for the six months ended June 30, 2020 was $278,515 (2019 – $134,844) from sales of dried cannabis to licensed producers and retail sales for the adult-use market in Canada. The total quantity of cannabis sold during the six months ended June 30, 2020 was 42,739 grams (June 30, 2019 – 24,517) at an average sale price of $6.52 per gram (June 30, 2019 – $5.5).

“With the global impact from the COVID-19 pandemic we remain operational while adjusting our priorities and spending to adapt appropriately. We continued to grow in the second quarter and put in place additional pieces that we believe will continue to propel Benchmark forward.  Our Nursery Seed Licence, the addition of our third production license for our joint venture and the planned acquisition of a controlling interest in 1139000 BC Ltd. are all events that we expect to lead to a stronger second half of 2020.” Said William Ying, Benchmark CEO.

About Benchmark Botanics Inc.

 

Benchmark is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical and recreational markets in Canada. The Company’s business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp throughout Asia, in countries where it is legal to do so.

 

Benchmark is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint.

 

Benchmark’s 100% owned subsidiary, Potanicals Green Growers Inc. (“Potanicals) is a Health Canada licensed producer under the Cannabis Act and its regulations. The Company is producing at its indoor Peachland, BC Cannabis Complex and is constructing a Phase II expansion of an additional 10,000 square foot extraction facility there. Along with cultivation and production, the company’s Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetic improvements and is progressing towards CBD oil extraction and an EU-GMP certification.

 

As part of its expansion strategy, the Company and a joint venture partner acquired a second facility, a 4-acre Greenhouse Operation in Pitt Meadows, BC. The Company, through Potanicals, received its second cultivation license, effective November 29, 2019, from Health Canada for that Pitt Meadow greenhouse.

 

For further information, please visit the Company’s website at www.benchmarkbotanics.com or the Company’s profile at www.sedar.com.

 

If you would like to be added to Benchmark’s news distribution list, please sign up at Investor Relations info@bbtinc.ca

 

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ “William Ying”
William Ying
Chief Executive Officer

Tel: 604-238-0005
www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.